Clinical Trial Update: A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 open-label trial evaluating Brentuximab Vedotin in systemic anaplastic large cell lymphoma, with results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Brentuximab vedotin (Adcetris) (brentuximab vedotin)

Snippet

Sponsor: Seagen Inc. | Conditions: Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin | Phase 2 | Status: COMPLETED | Results posted: 2011-10-26